Rafael de la Torre Selected Research

Anxiety Disorders (Anxiety Disorder)

1/2015	Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: relationship to psychiatric comorbidity.
11/2013	Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rafael de la Torre Research Topics

Disease

15	Cognitive Dysfunction 09/2023 - 01/2011
11	Obesity 05/2024 - 01/2013
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 11/2009
7	Substance-Related Disorders (Drug Abuse) 04/2022 - 01/2004
7	Down Syndrome (Down's Syndrome) 02/2020 - 01/2012
6	Body Weight (Weight, Body) 05/2024 - 01/2013
6	Cocaine-Related Disorders (Cocaine Addiction) 07/2021 - 11/2013
6	Mental Disorders (Mental Disorder) 02/2021 - 01/2013
5	Alzheimer Disease (Alzheimer's Disease) 06/2023 - 01/2015
5	Inflammation (Inflammations) 01/2020 - 07/2010
5	Atherosclerosis 12/2015 - 02/2009
4	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2023 - 10/2007
4	Schizophrenia (Dementia Praecox) 01/2023 - 07/2014
4	Neoplasms (Cancer) 01/2022 - 01/2007
4	Insulin Resistance 01/2022 - 08/2007
4	COVID-19 08/2021 - 01/2020
4	Fragile X Syndrome (Martin Bell Syndrome) 01/2021 - 05/2013
4	Alcoholism (Alcohol Abuse) 10/2020 - 09/2017
3	Fatty Liver 05/2024 - 10/2015
3	Gambling (Pathological Gambling) 11/2023 - 10/2014
3	Anorexia Nervosa 09/2023 - 09/2015
3	Neuroinflammatory Diseases 07/2023 - 10/2019
3	Feeding and Eating Disorders (Eating Disorder) 01/2023 - 01/2013
3	Weight Loss (Weight Reduction) 01/2022 - 01/2020
3	Overweight 01/2022 - 01/2018
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 05/2018
3	Morbid Obesity 12/2019 - 11/2017
3	Mood Disorders (Mood Disorder) 01/2019 - 01/2010
3	Intellectual Disability (Idiocy) 01/2018 - 05/2013
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2021
2	Drug-Related Side Effects and Adverse Reactions 10/2015 - 02/2010
2	Anxiety Disorders (Anxiety Disorder) 01/2015 - 11/2013
2	Bulimia Nervosa 08/2014 - 11/2013
2	Hyperthermia 04/2008 - 04/2008
1	Memory Disorders (Memory Loss) 08/2023
1	Psychotic Disorders (Schizoaffective Disorder) 01/2023

Drug/Important Bio-Agent (IBA)

17	Olive OilIBA 07/2023 - 01/2007
13	EndocannabinoidsIBA 09/2023 - 01/2013
12	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2013
8	LipidsIBA 01/2022 - 11/2013
7	CannabinoidsIBA 01/2023 - 01/2013
7	Proteins (Proteins, Gene)FDA Link 04/2021 - 02/2010
6	Cocaine (Cocaine HCl)IBA 07/2015 - 03/2007
6	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 01/2011 - 04/2004
5	Fatty Acids (Saturated Fatty Acids)IBA 05/2024 - 01/2013
5	3,4-dihydroxyphenylethanol (hydroxytyrosol)IBA 05/2024 - 09/2010
5	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2021 - 07/2016
4	AntioxidantsIBA 05/2024 - 09/2010
4	EnzymesIBA 05/2024 - 02/2010
4	anandamide (arachidonylethanolamide)IBA 11/2023 - 01/2019
3	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 11/2023 - 01/2022
3	Indicators and Reagents (Reagents)IBA 01/2023 - 08/2021
3	oleoylethanolamideIBA 01/2022 - 01/2015
3	4-hydroxyphenylethanolIBA 10/2021 - 09/2010
3	Peptides (Polypeptides)IBA 03/2016 - 01/2015
3	Glucose (Dextrose)FDA LinkGeneric 09/2015 - 07/2014
3	oxidized low density lipoproteinIBA 07/2015 - 09/2010
3	CholesterolIBA 01/2015 - 07/2014
2	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 08/2023 - 01/2015
2	Apolipoproteins E (ApoE)IBA 06/2023 - 01/2021
2	JZL 184IBA 10/2022 - 01/2017
2	lysophosphatidic acidIBA 04/2022 - 10/2020
2	Cholecystokinin (Pancreozymin)IBA 02/2022 - 02/2016
2	Methamphetamine (Desoxyn)FDA LinkGeneric 01/2022 - 01/2018
2	palmidrolIBA 01/2022 - 01/2015
2	N-acylethanolaminesIBA 01/2022 - 01/2015
2	IsoflavonesIBA 07/2021 - 01/2019
2	Analgesics (Analgesic Drugs)IBA 01/2021 - 10/2020
2	Insulin (Novolin)FDA Link 01/2021 - 09/2015
2	Fragile X Mental Retardation ProteinIBA 01/2021 - 05/2013
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2020 - 01/2015
2	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 12/2019 - 12/2017
2	Monoacylglycerol LipasesIBA 10/2019 - 01/2013
2	Ethanol (Ethyl Alcohol)IBA 01/2019 - 05/2015
2	Oleic Acid (Oleate)IBA 11/2018 - 10/2015
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 11/2018 - 01/2013
2	Acetaminophen (Paracetamol)FDA LinkGeneric 12/2017 - 11/2017
2	Caffeine (No Doz)FDA LinkGeneric 12/2017 - 11/2017
2	OrexinsIBA 11/2016 - 03/2016
2	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 01/2007
2	Amphetamine (Amfetamine)FDA LinkGeneric 10/2015 - 01/2004
2	PolyphenolsIBA 07/2015 - 05/2012
2	CytokinesIBA 07/2015 - 01/2015
2	Triglycerides (Triacylglycerol)IBA 01/2015 - 08/2007
2	Interleukin-6 (Interleukin 6)IBA 01/2015 - 09/2013
1	Ether (Diethyl Ether)IBA 05/2024
1	Fibric Acids (Fibrates)IBA 05/2024
1	Serum AlbuminIBA 09/2023
1	2-chloro-5-nitrobenzanilideIBA 08/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	Cyclin-Dependent Kinase 5IBA 01/2023
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2023
1	Disks Large Homolog 4 ProteinIBA 01/2023

Therapy/Procedure

16	Mediterranean Diet 02/2022 - 01/2007
7	Therapeutics 09/2023 - 01/2012
4	Cognitive Training 01/2021 - 07/2016
3	Bariatric Surgery 12/2019 - 11/2017
2	Glycemic Control 01/2021 - 01/2021
2	Fat-Restricted Diet (Diet, Fat Restricted) 05/2014 - 06/2007